Tris Pharma CEO Discusses 25-Year Strategic Evolution
Ketan Mehta, the founder and CEO of Tris Pharmaceutical, provided insights into the company's strategic evolution over its twenty-five-year history in an interview with Pharmaceutical Executive. Initially established with a focus on oral technology platforms, the company has significantly broadened its scope to address specific therapeutic areas. Mehta explained that while the firm continues to leverage its core technology where opportunities arise, it has shifted its primary focus toward neurology and neuroscience. Currently, Tris Pharma maintains a commercial portfolio featuring ADHD products and is developing a pipeline that includes treatments for narcolepsy, spasticity, pain management, and addiction. The discussion also covered Mehta's approaches to maximizing drug impact and navigating diverse regulatory environments. This overview highlights how the pharmaceutical company adapted its business model from a pure technology provider to a specialized developer of neurological and psychiatric treatments, reflecting broader changes in the industry and the company's response to market demands over nearly three decades.
Wire timeline
Tris Pharma CEO Discusses 25-Year Strategic Evolution
Ketan Mehta, the founder and CEO of Tris Pharmaceutical, provided insights into the company's strategic evolution over its twenty-five-year history in an interview with Pharmaceutical Executive. Initially established with a focus on oral technology platforms, the company has significantly broadened its scope to address specific therapeutic areas. Mehta explained that while the firm continues to leverage its core technology where opportunities arise, it has shifted its primary focus toward neurology and neuroscience. Currently, Tris Pharma maintains a commercial portfolio featuring ADHD products and is developing a pipeline that includes treatments for narcolepsy, spasticity, pain management, and addiction. The discussion also covered Mehta's approaches to maximizing drug impact and navigating diverse regulatory environments. This overview highlights how the pharmaceutical company adapted its business model from a pure technology provider to a specialized developer of neurological and psychiatric treatments, reflecting broader changes in the industry and the company's response to market demands over nearly three decades.
PharmExec articles